DTIL - Precision BioSciences, Inc.
| Previous Close | 18.51 |
| Open | 18.70 |
| Bid | 19.75 x 1100 |
| Ask | 19.77 x 1000 |
| Day's Range | 18.60 - 20.67 |
| 52 Week Range | 6.24 - 20.67 |
| Volume | 1,533,962 |
| Avg. Volume | 560,450 |
| Market Cap | 998.478M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Precision BioSciences, Inc. (DTIL) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Precision BioSciences, Inc. (DTIL).
- American City Business Journals
Executive Voice: His firm peers into genes to find clues to cure cancer
For Matthew Kane, the near future of life sciences is full of revolutionary possibilities – especially for new and upcoming techniques such as gene editing.
- Insider Monkey
Is Precision BioSciences, Inc. (DTIL) Going To Burn These Hedge Funds ?
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 28. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
- Simply Wall St.
We Think Precision BioSciences (NASDAQ:DTIL) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- Simply Wall St.
How Much Of Precision BioSciences, Inc. (NASDAQ:DTIL) Do Insiders Own?
If you want to know who really controls Precision BioSciences, Inc. (NASDAQ:DTIL), then you'll have to look at the...
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Precision BioSciences, Inc. (DTIL)
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
- Motley Fool
Is the Newest Gene Editing Stock a Buy?
Precision BioSciences raised over $170 million in net proceeds from its initial public offering in late March.
- Associated Press
Precision BioSciences: 1Q Earnings Snapshot
The Durham, North Carolina-based company said it had a loss of $1.99 per share. Losses, adjusted for non-recurring costs, were $1.19 per share. The genome editing company posted revenue of $5.5 million ...
- Benzinga
The Precision Biosciences IPO: What You Need To Know
Gene therapy is in vogue among biotech investors, and Precision Biosciences (DTIL), which operates in the sector, is planning an initial public offering . The Offering The company will issue 7.9 million ...
- Benzinga
IPO Outlook For The Week: Biopharm, Gene Editor And Lyft
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Genfit S.A. (GNFT) will issue 5 million shares at $26.33 each Wednesday ...
